Other languages Ascendis Pharma A/S

Equities

ASND

US04351P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			After market 06:24:09 pm
141.1 ^USD	+0.06%		141.6	+0.32%

May. 02	Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 02	Earnings Flash (ASND) ASCENDIS PHARMA Reports Q1 Revenue EUR95.9M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism	Apr. 24
Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	Apr. 24
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer	Feb. 29
European Equities Traded in the US as American Depositary Receipts Set to End Week Higher in Friday Trading	Feb. 16
European Equities Traded in US as American Depositary Receipts Move Slightly Higher in Friday Trading	Feb. 09
Ascendis Pharma Q4 Net Loss Narrows, Revenue Rises	Feb. 07
Ascendis Pharma A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07
Ascendis Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading	Feb. 01
Ascendis Pharma A/S Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism	Jan. 31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ascendis Pharma A/S

Equities

ASND

US04351P1012

Other languages

Filters